McGregor A, Scanlon M F, Hall R
Ann Med Interne (Paris). 1982;133(1):51-7.
Prolactin-secreting pituitary adenomas have only recently been recognised as distinct entities, but probably represent the most frequent type of secreting pituitary adenomas. As they occur mainly in young women during the period of genital activity, and as therapeutic success depends on their being detected while they are still small, accent is currently being placed on early diagnosis and specific therapy. Early diagnosis depends mainly on the results of exploration of the neuro-endocrine factors of the hypothalamus-pituitary axis. Treatment, while dependent upon the attitudes of the different teams, has been transformed by the re-introduction of the trans-sphenoidal surgical approach, and the availability of bromocriptine, an orally active dopamine agonist. Their combined use has produced selective successful results in the treatment of microadenomas. Bromocriptine can reduce the size of large prolactin-secreting adenomas, and is probably a better choice than surgery because of the high failure rate of trans-sphenoid operations in the case of macroadenomas, Long-term results of these two therapeutic procedures have still to be evaluated.
分泌催乳素的垂体腺瘤直到最近才被确认为独立的实体，但可能是分泌性垂体腺瘤中最常见的类型。由于它们主要发生在生殖活动期的年轻女性中，并且治疗成功与否取决于在肿瘤仍较小时被发现，因此目前重点在于早期诊断和特异性治疗。早期诊断主要依赖于下丘脑 - 垂体轴神经内分泌因子的检查结果。治疗虽然取决于不同团队的态度，但经蝶窦手术方法的重新引入以及口服活性多巴胺激动剂溴隐亭的可得性使其发生了改变。它们的联合使用在微腺瘤的治疗中取得了选择性的成功结果。溴隐亭可缩小大型分泌催乳素腺瘤的大小，并且由于在大腺瘤病例中经蝶窦手术的失败率较高，溴隐亭可能比手术是更好的选择。这两种治疗方法的长期结果仍有待评估。
